Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription 22.04.2024 2 Ann Thorac Surg 2 Arch Pathol Lab Med 8 BMC Cancer 1 Cancer Chemother Pharmacol 1 Cancer Lett 5 Cancer Res 5 Clin Cancer Res 1 Clin Lung Cancer 2 Eur J Cardiothorac Surg 1 Eur Respir J 1 Int J Cancer 4 Int J Radiat Oncol Biol Phys 2 J Thorac Cardiovasc Surg 3 J Thorac Oncol 1 JAMA Oncol 4 Lung Cancer 2 Mol Carcinog 1 Nat Genet 1 Nat Med 1 Oncogene 1 Oncol Rep 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Thorac Surg

1. TAKAHASHI T
   Study-design of adjuvant chemotherapy for lung cancer: A cart before the horse.
   Ann Thorac Surg. 2024 Apr 13:S0003-4975(24)00285.
   PubMed        
   
   
2. SHAHZAD MH, Spicer JD, Rusch VW, Kneuertz PJ, et al
   Perioperative Immunotherapy for Node-Negative Non-Small Cell Lung Cancer - Current Evidence and Future Directions.
   Ann Thorac Surg. 2024 Apr 13:S0003-4975(24)00280.
   PubMed         Abstract available
   
   

   
   Arch Pathol Lab Med

3. SUN Q, Li W, Yang D, Lin PP, et al
   The Presence of Small-Size Circulating Tumor Cells Predicts Worse Prognosis in Non-Small Cell Lung Cancer Patients.
   Arch Pathol Lab Med. 2024 Apr 18. doi: 10.5858/arpa.2023-0455.
   PubMed         Abstract available
   
   
4. SHOLL LM, Awad M, Basu Roy U, Beasley MB, et al
   Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International As
   Arch Pathol Lab Med. 2024 Apr 16. doi: 10.5858/arpa.2023-0536.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. HUANG Y, Chen D, Bai Y, Zhang Y, et al
   ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
   BMC Cancer. 2024;24:452.
   PubMed         Abstract available
   
   
6. WU JR, Chen VC, Fang YH, Hsieh CC, et al
   The associates of anxiety among lung cancer patients: Dehydroepiandrosterone (DHEA) as a potential biomarker.
   BMC Cancer. 2024;24:476.
   PubMed         Abstract available
   
   
7. MIAO SN, Chai MQ, Liu XY, Wei CY, et al
   Exercise accelerates recruitment of CD8(+) T cell to promotes anti-tumor immunity in lung cancer via epinephrine.
   BMC Cancer. 2024;24:474.
   PubMed         Abstract available
   
   
8. LI Y, Chen Z, Tian S, Han X, et al
   Stereotactic ablative brachytherapy versus percutaneous microwave ablation as salvage treatments for lung oligometastasis from colorectal cancer.
   BMC Cancer. 2024;24:481.
   PubMed         Abstract available
   
   
9. MIMURA C, Takamiya R, Fujimoto S, Fukui T, et al
   Utility of bronchoscopically obtained frozen cytology pellets for next-generation sequencing.
   BMC Cancer. 2024;24:489.
   PubMed         Abstract available
   
   
10. XU K, Lu W, Yu A, Wu H, et al
    Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
    BMC Cancer. 2024;24:491.
    PubMed         Abstract available
    
    
11. OKAYAMA T, Suzuki K, Morishita S, Inoue J, et al
    Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:495.
    PubMed         Abstract available
    
    
12. KONG C, Yin X, Zou J, Ma C, et al
    The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung.
    BMC Cancer. 2024;24:454.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

13. XU X, Liu Y, Gong Q, Ma L, et al
    PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2024 Apr 12. doi: 10.1007/s00280-024-04668.
    PubMed         Abstract available
    
    

    
    Cancer Lett

14. LUO J, Cheng K, Ji X, Gao C, et al
    Anlotinib enhanced CD8(+) T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer.
    Cancer Lett. 2024;591:216892.
    PubMed         Abstract available
    
    

    
    Cancer Res

15. BOUMELHA J, de Castro A, Bah N, Cha H, et al
    CRISPR-Cas9 screening identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer.
    Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2627.
    PubMed         Abstract available
    
    
16. RUMDE PH, Burns TF
    A Path to Persistence after EGFR Inhibition.
    Cancer Res. 2024;84:1188-1190.
    PubMed         Abstract available
    
    
17. PETRONI G, Pillozzi S, Antonuzzo L
    Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.
    Cancer Res. 2024;84:1199-1209.
    PubMed         Abstract available
    
    
18. LAU A, Blenis J, Burgos-Barragan G
    Decoding Serine Metabolism: Unveiling Novel Pathways for Evolving Cancer Therapies.
    Cancer Res. 2024;84:1191-1194.
    PubMed         Abstract available
    
    
19. ZHU X, Fu Z, Dutchak K, Arabzadeh A, et al
    Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer.
    Cancer Res. 2024;84:1333-1351.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

20. LEE EJ, Oh SY, Lee YW, Kim JY, et al
    Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.
    Clin Cancer Res. 2024;30:1582-1594.
    PubMed         Abstract available
    
    
21. OH HJ, Bae SC, Oh IJ, Park CK, et al
    Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.
    Clin Cancer Res. 2024;30:1478-1487.
    PubMed         Abstract available
    
    
22. GRAZINI U, Markovets A, Ireland L, O'Neill D, et al
    Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2540.
    PubMed         Abstract available
    
    
23. PERESSINI M, Garcia-Campelo R, Massuti B, Marti C, et al
    Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-24-0104.
    PubMed         Abstract available
    
    
24. ZUGAZAGOITIA J, Osma H, Baena J, Ucero AC, et al
    Facts and hopes on cancer immunotherapy for small cell lung cancer.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

25. DONINGTON J, Hu X, Zhang S, Song Y, et al
    Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2024 Mar 22:S1525-7304(24)00041.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

26. SACHS E, Jackson V, Al-Ameri M, Sartipy U, et al
    Uniportal video-assisted thoracic surgery: segmentectomy versus lobectomy-early outcomes.
    Eur J Cardiothorac Surg. 2024;65:ezae127.
    PubMed         Abstract available
    
    
27. BRUNELLI A
    Segmentectomy: lower surgical quality is associated with poorer outcomes.
    Eur J Cardiothorac Surg. 2024;65:ezae144.
    PubMed        
    
    

    
    Eur Respir J

28. LEWIS KE
    Smoking cessation at lung cancer screening: joining (life-saving) dots.
    Eur Respir J. 2024;63:2400550.
    PubMed        
    
    

    
    Int J Cancer

29. ZHANG B, Li C, Wu J, Zhang J, et al
    DeepCG: A cell graph model for predicting prognosis in lung adenocarcinoma.
    Int J Cancer. 2024;154:2151-2161.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

30. LOMBARDO J, Castillo E, Castillo R, Miller R, et al
    Prospective trial of Functional Lung Avoidance Radiation Therapy for Lung Cancer: Quality of Life Report.
    Int J Radiat Oncol Biol Phys. 2024 Apr 11:S0360-3016(24)00476.
    PubMed         Abstract available
    
    
31. MEREDITH EG, Filion E, Faria S, Kundapur V, et al
    Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET).
    Int J Radiat Oncol Biol Phys. 2024 Apr 11:S0360-3016(24)00480.
    PubMed         Abstract available
    
    
32. ZHANG Q, Fan S, Xu X, Du S, et al
    Efficacy and Toxicity of Moderately Hypofractionated Radiotherapy with Helical TomoTherapy versus Conventional Radiotherapy in Patients with Unresectable Stage III Non-Small-Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicentre, Randomized
    Int J Radiat Oncol Biol Phys. 2024 Apr 15:S0360-3016(24)00450.
    PubMed         Abstract available
    
    
33. MIDRONI J, Salunkhe R, Liu Z, Chow R, et al
    Incorporating functional lung imaging (FLI) into radiation therapy planning in patients with lung cancer: A systematic review and meta-analysis.
    Int J Radiat Oncol Biol Phys. 2024 Apr 15:S0360-3016(24)00481.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

34. JONES DR, Bueno R, Harpole DH Jr, Vaporciyan AA, et al
    Thoracic Surgical Oncology Group: An American Association for Thoracic Surgery Clinical Trials Initiative.
    J Thorac Cardiovasc Surg. 2024;167:1584-1588.
    PubMed        
    
    
35. ZHOU N, Ripley-Gonzalez JW, Zhang W, Xie K, et al
    Preoperative Exercise Training Decreases Complications of Minimally Invasive Lung Cancer Surgery- A Randomized Controlled Trial.
    J Thorac Cardiovasc Surg. 2024 Apr 11:S0022-5223(24)00296.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

36. ERNST SM, van Marion R, Atmodimedjo PN, de Jonge E, et al
    Clinical utility of circulating tumor DNA in patients with advanced KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib.
    J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00165.
    PubMed         Abstract available
    
    
37. HORNE A, Harada K, Brown KD, Chua KLM, et al
    Treatment response biomarkers: working towards personalised radiotherapy for lung cancer.
    J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00164.
    PubMed         Abstract available
    
    
38. KIM IH, Lee GD, Choi S, Kim HR, et al
    Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
    J Thorac Oncol. 2024 Apr 11:S1556-0864(24)00160.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

39. SZLOSAREK PW, Creelan BC, Sarkodie T, Nolan L, et al
    Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
    JAMA Oncol. 2024;10:475-483.
    PubMed         Abstract available
    
    

    
    Lung Cancer

40. TOZUKA T, Noro R, Mizutani H, Kurimoto F, et al
    Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Lung Cancer. 2024;191:107540.
    PubMed         Abstract available
    
    
41. DE RUITER JC, van der Noort V, van Diessen JNA, Smit EF, et al
    The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
    Lung Cancer. 2024;191:107792.
    PubMed         Abstract available
    
    
42. LIU S, Graves N, Tan AC
    The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population.
    Lung Cancer. 2024;191:107794.
    PubMed         Abstract available
    
    
43. BADE BC, Zhao J, Li F, Tanoue L, et al
    Trends and predictors of Quality of Life in lung cancer survivors.
    Lung Cancer. 2024;191:107793.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

44. YANG Y, Tian Z, He L, Meng H, et al
    RhoGDIbeta inhibition via miR-200c/AUF1/SOX2/miR-137 axis contributed to lncRNA MEG3 downregulation-mediated malignant transformation of human bronchial epithelial cells.
    Mol Carcinog. 2024;63:977-990.
    PubMed         Abstract available
    
    
45. DU X, Cheng C, Yang Y, Fan B, et al
    NSUN2 promotes lung adenocarcinoma progression through stabilizing PIK3R2 mRNA in an m(5)C-dependent manner.
    Mol Carcinog. 2024;63:962-976.
    PubMed         Abstract available
    
    

    
    Nat Genet

46. 
    Identifying regulatory loci across 38 lung cell types.
    Nat Genet. 2024;56:561-562.
    PubMed        
    
    

    
    Nat Med

47. TAMMEMAGI MC, Darling GE, Schmidt H, Walker MJ, et al
    Risk-based lung cancer screening performance in a universal healthcare setting.
    Nat Med. 2024;30:1054-1064.
    PubMed         Abstract available
    
    

    
    Oncogene

48. ZHANG T, Su F, Wang B, Liu L, et al
    Ubiquitin specific peptidase 38 epigenetically regulates KLF transcription factor 5 to augment malignant progression of lung adenocarcinoma.
    Oncogene. 2024;43:1190-1202.
    PubMed         Abstract available
    
    

    
    Oncol Rep

49. GAO Y, Zhang G, Liu J, Li H, et al
    [Retracted] Tissue?specific transplantation antigen P35B functions as an oncogene and is regulated by microRNA?125a?5p in lung cancer.
    Oncol Rep. 2024;51:76.
    PubMed         Abstract available
    
    

    
    PLoS One

50. RADWAN AA, Alanazi F, Al-Dhfyan A
    Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.
    PLoS One. 2024;19:e0298326.
    PubMed         Abstract available
    
    
51. LI H, Huntington S, Gross C, Wang SY, et al
    Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease.
    PLoS One. 2024;19:e0300789.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.